These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1638 related items for PubMed ID: 12860938

  • 1. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.
    J Clin Oncol; 2003 Jul 15; 21(14):2636-44. PubMed ID: 12860938
    [Abstract] [Full Text] [Related]

  • 2. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 15; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 3. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline.
    Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
    J Thorac Oncol; 2006 Jul 15; 1(6):591-601. PubMed ID: 17409924
    [Abstract] [Full Text] [Related]

  • 4. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.
    J Clin Oncol; 2023 Apr 20; 41(12):2125-2133. PubMed ID: 37068377
    [Abstract] [Full Text] [Related]

  • 5. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 20; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

  • 6. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ, Fink TH, Latz JE, Hossain AM, Musib LC, Thomas M.
    Clin Cancer Res; 2009 Jan 01; 15(1):382-9. PubMed ID: 19118069
    [Abstract] [Full Text] [Related]

  • 7. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
    Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, Nackaerts K, Lianes P, Vogelzang NJ.
    Ann Oncol; 2005 Jun 01; 16(6):923-7. PubMed ID: 15824080
    [Abstract] [Full Text] [Related]

  • 8. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
    Green J, Dundar Y, Dodd S, Dickson R, Walley T.
    Cochrane Database Syst Rev; 2007 Jan 24; 2007(1):CD005574. PubMed ID: 17253564
    [Abstract] [Full Text] [Related]

  • 10. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 24; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 11. A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.
    Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.
    Lung Cancer; 2012 Sep 24; 77(3):567-71. PubMed ID: 22770372
    [Abstract] [Full Text] [Related]

  • 12. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
    Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M.
    Ann Oncol; 2008 Feb 01; 19(2):370-3. PubMed ID: 18156144
    [Abstract] [Full Text] [Related]

  • 14. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK, Ye Z, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Monberg MJ, Jänne PA, Pemetrexed Expanded Access Program Investigators.
    Lung Cancer; 2007 Feb 01; 55(2):187-94. PubMed ID: 17092602
    [Abstract] [Full Text] [Related]

  • 15. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients.
    Nakagawa K, Yamazaki K, Kunitoh H, Hida T, Gemba K, Shinkai T, Ichinose Y, Adachi S, Nambu Y, Saijo N, Fukuoka M.
    Jpn J Clin Oncol; 2008 May 02; 38(5):339-46. PubMed ID: 18434338
    [Abstract] [Full Text] [Related]

  • 17. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul 02; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 18. Nursing considerations for administering pemetrexed (Alimta) in combination with cisplatin for malignant pleural mesothelioma.
    Orbaugh KK.
    Clin J Oncol Nurs; 2004 Jun 02; 8(3):242-7. PubMed ID: 15208818
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA, Favaretto AG, Grossi F, Bidoli P, Del Conte G, Ceribelli A, Bearz A, Morenghi E, Cavina R, Marangolo M, Parra HJ, Santoro A.
    J Clin Oncol; 2006 Mar 20; 24(9):1443-8. PubMed ID: 16549838
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.
    J Clin Oncol; 2008 Mar 20; 26(9):1465-71. PubMed ID: 18349397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.